Status:
COMPLETED
Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody
Lead Sponsor:
AstraZeneca
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is an open-label, 2-arm study in which patients are randomized to receive either the formulation that is being used in clinical trials or the formulation that will be used when if the drug become...
Eligibility Criteria
Inclusion
- Stage III or Stage IV melanoma
- No evidence of disease following resection of melanoma lesions
- Recovered from all prior surgical or adjuvant treatment-related toxicities
Exclusion
- History of chronic inflammatory or autoimmune disease
- History of inflammatory bowel disease
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT00431275
Start Date
June 1 2006
End Date
February 1 2008
Last Update
June 6 2012
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Scottsdale, Arizona, United States, 85260
2
Research Site
Aurora, Colorado, United States, 80010
3
Research Site
Aventura, Florida, United States, 33180
4
Research Site
Miami Beach, Florida, United States, 33140